1.Study of resident dermatologist standardization training mode
Zhili GUO ; Jun GU ; Zhuo CHEN
Chinese Journal of Medical Education Research 2013;(7):742-744
Resident doctor standardization training is the base of dermatologist training. We set up the specialist standardization training system according to our hospital's training practice. The dermatolo-gist standardization training mode was set up through tutor responsibility rule , internet learning platform and problem-based learning methods. The teaching level for dermatologists was upgraded by using above methods.
3.Risk of Recurrence or Metastasis of Breast Cancer by LNG-IUS: A Meta-analysis
Ya'nan WANG ; Wenping LU ; Heting MEI ; Yongjia CUI ; Zhili ZHUO
Cancer Research on Prevention and Treatment 2022;49(8):786-791
Objective To evaluate the risk of recurrence or metastasis of breast cancer by LNG-IUS via meta-analysis. Methods We searched literature in the PubMed, Web of Science, Cochrane, EMBASE, CBM, CNKI, VIP, and WanFang database.The retrieval period was from January 2014 to October 2021.Data extraction and quality evaluation were conducted for the included randomized controlled study (RCT) to analyze whether LNG-IUS can increase the risk of recurrence or metastasis of breast cancer. Results A total of 1309 Chinese and English studies were retrieved; 5 RCTs were included in this study, and 446 patients were enrolled.The combined total effect value in the fixed-effect model with RD (95%
4.Exploring the Clinical Approach of Treating Breast Cancer in Traditional Chinese Medicine Through Syndrome Differentiation Based on the Nature and Intensity of the Cancer Toxin
Zhili ZHUO ; Qingya SONG ; Wenping LU ; Xiaoqing WU ; Yongjia CUI ; Dongni ZHANG ; Lei CHANG ; Heting MEI
Chinese Journal of Information on Traditional Chinese Medicine 2024;31(8):176-181
Cancer toxin is a specific pathogenesis leading to the heterogeneity of breast cancer.The nature and virulence of the cancer toxin determine the differences in the heterogeneity of breast cancer,which can dynamically evolve over time and space,resulting in varying invasion abilities and characteristics of the tumor.Cancer cells in the primary lesion possess"toxicity"that targets specific organs for metastasis,and cancer toxins can influence the metastatic propensity of different types of breast cancer.Therefore,breast cancer treatment strategies based on the theory of cancer toxins emphasize the continuous eradication of the cancer toxin,focusing on differentiating its strength and nature,protecting unaffected areas first,identifying the state based on symptoms,and targeting accordingly to combat resistance arising from tumor heterogeneity.This article aims to provide a new theoretical basis for the treatment strategies of different types of breast cancer.
5.Treatment outcomes and prognostic analysis of 61 Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
Xiangzong ZENG ; Na WEI ; Yi'ni WANG ; Jingshi WANG ; Jia ZHANG ; Lin WU ; Wenqiu HUANG ; Zhuo GAO ; Ruijun PEI ; Jianhang CHEN ; Zhili JIN ; Zhao WANG
Chinese Journal of Hematology 2015;36(6):507-510
OBJECTIVETo investigate the outcomes, survival status, and the prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) patients.
METHODSA retrospective study was carried out to analyze the clinical data of 61 EBV-HLH cases, from January 2008 to July 2014. Prognostic factors were analyzed through COX model (single factor and multiple factors).
RESULTSA total of 246 patients with HLH were diagnosed, among which 102 cases were with EBV infection (including 61 EBV-HLH, 36 lymphoma associated HLH, 5 primary HLH. Among the 61 cases, 40 were male and 21 were female, with a ration of 1.9:1. The median age was 28 years (range, 12-78). 1, 3, 6 and 12-month overall survival rates of 61 EBV-HLH were 65.6%, 47.5%, 32.4%, and 25.0%, respectively. The median follow-up time was 3 (0.5-28) months. 12 patients didn't use etoposide within 4 weeks after diagnosis, while HLH-94 protocol was used in 33 patients and HLH-2004 protocol was used in 16 patients. Response rates of theses three groups were 33.3%, 51.5%, and 43.8%, respectively (P=0.401). There was statistically difference between the group without etoposide and the HLH-94/ HLH-2004 group in the overall survival rate (P=0.033). Serum albumin level (P=0.033) and whether EBV could became negative (P=0.010) were independent predictors for EBV-HLH.
CONCLUSIONEBV-HLH patients have severe clinical feature and poor prognosis. Early application of immune chemotherapy based on etoposide can improve survival. Serum albumin level and whether EBV can become negative are independent prognostic factors for survival.
Adolescent ; Adult ; Aged ; Child ; Epstein-Barr Virus Infections ; Etoposide ; Female ; Herpesvirus 4, Human ; Humans ; Lymphohistiocytosis, Hemophagocytic ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Survival Rate ; Treatment Outcome ; Young Adult